PROSTEP Drug Patent Profile

When do Prostep patents expire, and when can generic versions of Prostep launch?

Prostep is a drug marketed by Aveva and is included in one NDA.

The generic ingredient in PROSTEP is nicotine. Thirty suppliers are listed for this compound. Additional details are available on the nicotine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prostep

A generic version of PROSTEP was approved as nicotine by DIFGEN PHARMS on October 20^th, 1997.

Summary for PROSTEP

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PROSTEP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aveva	PROSTEP	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	019983-003	Dec 23, 1998		DISCN	No	No
Aveva	PROSTEP	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	019983-004	Dec 23, 1998		DISCN	No	No

International Patents for PROSTEP

See the table below for patents covering PROSTEP around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	161721
Australia	1534988
Australia	607214
Canada	1333051	METHODE DE TRAITEMENT DES SYMPTOMES DE SEVRAGE LIES A L'ABANDON DU TABAC ET PREPARATIONS UTILISEES A CETTE FIN (METHOD FOR THE TREATMENT OF WITHDRAWAL SYMPTOMS ASSOCIATED WITH SMOKING CESSATION AND PREPARATIONS FOR USE IN SAID METHOD)
Germany	3856096

Last updated: April 27, 2026

PROSTEP (Drug): Investment Scenario and Fundamentals Analysis

What is PROSTEP and what is the investable asset?

No investable pharmaceutical “drug” asset named PROSTEP could be validated from authoritative public patent, regulatory, or product-registration sources within the available information. Without a confirmable active ingredient, formulation, dosage form, market authorization status, or documented patent family, an accurate fundamentals-and-investment scenario cannot be produced.

Can PROSTEP be mapped to a patent family and exclusivity landscape?

A complete investment-grade mapping requires at least one of the following, each tied to the marketed product or its manufacturing dossier:

• active ingredient and salt form
• strength and dosage form
• marketing authorization country scope (e.g., FDA, EMA, PMDA, etc.)
• a patent family with publication numbers (WO/EP/US) or granted national equivalents
• linkage to regulatory exclusivities (e.g., US PTE, SPC, data exclusivity)

No such mapping for “PROSTEP” is verifiable here, so the patent term, exclusivity term, generic/biosimilar entry risk, and litigation posture cannot be quantified.

What is the commercial basis for PROSTEP under a fundamentals model?

A fundamentals model requires at minimum:

• current sales (or proxy indicators like prescriptions, wholesaler distribution, tender volume)
• treatment indication(s), line of therapy, and label geography
• competitive set (reference products, authorized generics, alternative mechanisms)
• pricing and reimbursement context
• near-term trial pipeline or label expansion milestones tied to disclosed timelines

No PROSTEP product attributes or market footprint can be validated from this input set, so revenue drivers, margin structure, and probability-weighted near-term catalysts cannot be constructed.

Investment scenario: what outcome tree can be built?

An outcome tree requires specific, attributable drivers such as:

• patent grant and priority dates
• mean regulatory time to approval or label expansion
• trial readouts (phase, endpoints, comparators)
• safety and manufacturing constraints
• patent litigation schedule and injunction risk

With PROSTEP not mapped to any confirmable patent or regulatory artifact in the available context, the outcome tree cannot be grounded in facts.

Comparable framework: what benchmarks would be used if PROSTEP were identifiable?

If PROSTEP were identifiable, the investment framework would be benchmarked against:

• Patent cliff risk using document-level expiries (priority, grant, terminal disclaimers, SPC where applicable)
• Regulatory cliff risk using exclusivity expiration (data and market exclusivity)
• Clinical differentiation using MoA competitive positioning and label strength
• Adoption curve using uptake signals and payer policy
• Execution risk using CMC readiness indicators and site qualification

Those benchmarks cannot be instantiated for PROSTEP without the underlying drug identity.

---

Key Takeaways

• PROSTEP cannot be analyzed as an investment-grade pharmaceutical asset based on verifiable fundamentals from the provided prompt.
• A complete patent and exclusivity landscape, commercialization thesis, and probability-weighted investment scenario require a confirmable drug identity (active ingredient, formulation, regulatory status, and patent family references).
• Without that mapping, no actionable R&D or investment conclusion can be produced while remaining factual and accurate.

---

FAQs

1. What information is needed to build a patent-and-exclusivity map for a pharmaceutical drug?
   Patent publications/grants (WO/EP/US) and a regulatory linkage to the marketed product including active ingredient, salt, dosage form, and approval jurisdictions.

2. How do you quantify generic entry risk for a single drug asset?
   By building a document-level exclusivity timeline (priority-to-expiry, data exclusivity, market exclusivity, SPC where applicable) and overlaying any paragraph IV or equivalent litigation.

3. What fundamentals inputs drive a probability-weighted investment scenario?
   Indication, label geography, competitive set, sales trajectory, pricing and reimbursement, pipeline catalysts, trial readouts, and regulatory/CMC execution milestones.

4. How is the patent life translated into investment value in practice?
   By modeling forecast duration to patent/SPC expiration, factoring erosion from authorized competitors and infringement workarounds, then discounting by probability-weighted commercial adoption.

5. What is the fastest way to validate a drug’s investable identity for analysis?
   Cross-link the drug name to active ingredient and regulatory filings, then tie it to patent family publication identifiers.

---

References

No sources were cited because the PROSTEP drug identity and corresponding patents/regulatory records were not verifiably identifiable from the provided information.